Saves the questions and what to expect into your notes, next to the visit they belong to.
Keep this study
Lead
Astellas Pharma Global Development, Inc.
With
Pfizer
Age
18–any
Sex
MALE
Healthy volunteers
Not accepted
You may be eligible if
Patient Inclusion:
Patient may have M0 or M1 disease
Confirmed diagnosis of CRPC defined by both Testosterone at castrate levels, as evidenced by a serum testosterone level ≤ 1.73 nmol/L (50 ng/dL) and Clear progressive disease, as evidenced by a minimum of two rising PSA levels measured at least 7 days apart or new clinical or imaging evidence of progressive metastatic disease
Initiating the first or second line treatment for CRPC: including anti- androgens, androgen synthesis inhibitors, chemotherapy, immunotherapy or radionuclide therapy. Previous first line CRPC treatments are limited to: First generation anti-androgens (bicalutamide, flutamide, or nilutamide) or Sipuleucel-T
Patients may be enrolled within 90 days from the time of decision to treat or within 90 days of treatment initiation.
Willing and able to complete periodic patient-reported outcome (PRO) questionnaires, with or without assistance
Estimated life expectancy of ≥ 6 months
Caregiver Inclusion:
Meets the definition of an unpaid relative or friend who helps the patient with his or her activities of daily living
Willing and able to complete caregiver-reported outcome questionnaires over the course of the patient's participation in the study
You may not be if
Patient Exclusion:
Receiving concomitant treatment for other cancer (excluding basal cell carcinoma, squamous cell carcinoma and treatment for hormone sensitive prostate cancer) within 6 months prior to enrollment.
